Here are five key notes from the report:
1. Fourth quarter net sales were up 16.3 percent to $3.2 billion; full year net sales grew 13.9 percent to $11.3 billion. The net sales were up 6.7 percent year-over-year excluding the impact of acquisitions and foreign currency.
2. Earnings per diluted share are expected to be higher than the originally stated range of $5.75 to $5.80 due to strong organic net sales growth.
3. The company reported domestic net sales reached $8.2 billion in the full year, a 15.9 percent increase. International net sales were up 8.8 percent to $2.1 billion.
4. The full year net sales for each of the business segments were:
• Orthopedics: $4.4 billion, up 4.7 percent
• Medsurg: $4.9 billion, up 25.7 percent
• Neurotechnology and spine: $2 billion, up 9.8 percent
5. The fourth quarter net sales for each business segment were:
• Orthopedics: $1.2 billion, up 5.3 percent
• Medsurg: $1.4 million, up 31.4 percent
• Neurotechnology and spine: $524 million, up 8.3 percent
More articles on orthopedic devices:
Rhode Island Hospital joins INSPIRE study as 29th clinical site: 5 points
Expanding Orthopedics reports 100%+ sales growth for FLXfit cage—5 highlights
Where NuVasive will focus in the future—Alignment, radiation reduction and more
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
